Please read

Please read this notice carefully – it applies to all persons who view this site and, depending on where you are located may affect your rights and responsibilities. genedrive plc reserves the right to amend or update this notice at any time and you should, therefore, read it in full each time you visit this section of the site. The contents of this section of the website may be amended at any time, in whole or in part, at the sole discretion of genedrive plc.

I/We understand that:

By clicking on the "I Accept" button below, I/ We understand that I/We have read, understood and agreed to the above conditions and confirm that I am not a citizen, national or resident of the United States of America, Canada, Australia, the Republic of South Africa, New Zealand or Japan

connecting rod

Press releases

3rd Apr 2024

NICE recommends the Genedrive® CYP2C19-ID Kit

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, announces that the...

20th Dec 2023

Initial overseas orders of the Genedrive® MT-RNR1 ID Kit

genedrive plc (AIM: GDR), the point of care Pharmacogenetic testing company, announces that ini...

4th Dec 2023

Royal Sussex County Hospital, Brighton adopts the Genedrive® MT-RNR1 ID Kit for routine use Further expansion of hearing loss test into the NHS

genedrive plc (AIM: GDR), the point of care Pharmacogenetic testing company, announces the Gene...

connecting rod

Share price

Regulatory news

Latest reports

share price graph

05 April 2024

Interim Presentation 31 December 2023